LGM Pharma, a leading provider of tailored API sourcing, contract analytical testing, and CDMO services, has announced the second phase of its growth strategy, investing an additional $9 million in its Rosenberg, Texas, and Colorado Springs, Colorado, facilities. 

 

This follows a $6 million expansion in Rosenberg in 2025 and signals a major push to boost commercial capacity, expand R&D capabilities, and meet rising demand for US-based drug product manufacturing.

 

In Rosenberg, $4 million will fund expanded commercial-scale manufacturing suites for suppositories, addressing surging demand in women’s health products. Upgrades will also enhance R&D for formulations including suppositories, solutions, suspensions, and semi-solids. The facility will remain fully operational throughout construction, with work already underway.

 

Meanwhile, the Colorado Springs site will receive $5 million to grow commercial manufacturing for high-value oral solid dose (OSD) products, including orally disintegrating tablets (ODTs). 

 

The facility, a center of excellence for OSD development, is slated for expansion completion later this year, supporting the booming domestic OSD market, which was valued at $43.65 billion globally in 2024, with North America representing roughly 40.5% of production.

 

“These multi-site investments totaling $15 million reflect our continued commitment to strengthening pharmaceutical supply chains in the United States,” said Prasad Raje, Chief Executive Officer of LGM Pharma. 

 

“Today’s pharma companies need partners that are both resilient and integrated across the full product lifecycle. By reinforcing domestic drug product manufacturing at the downstream end of the supply chain, closer to end markets, and leveraging our global API sourcing capabilities upstream, we create a balanced end-to-end model. This gives customers greater control and visibility as they move products from development to commercialization.”

 

Earlier in the supply chain, LGM Pharma supports 505(b)(2), NDA, and ANDA programs through a network of more than 220 pre-qualified API manufacturers. By combining global drug substance sourcing with expanded U.S. finished dose development and manufacturing, the company offers integrated support across the full drug product lifecycle.

 

Hamilton Lenox, Chief Commercial Officer, highlighted the smooth execution of the expansion: “We are executing this next phase of expansion while keeping both facilities fully operational. Our teams are experienced in managing complex upgrades without sacrificing quality or disrupting customer supply, which remain our top operational priorities. 

 

"Rather than overextending in a single phase, we are executing these enhancements incrementally to expand capabilities and capacity while ensuring operational continuity. This approach allows us to strengthen infrastructure, support customer growth, and scale in response to market demand.”